Yüklüyor......
A Case of Interstitial Lung Disease Probably Related to Rituximab Treatment
A 44-year-old male developed interstitial lung disease (ILD) during treatment with rituximab (375 mg/m(2) weekly intravenous × 4 weeks) for the management of immune thrombocytopenia (ITP). After 1 month of treatment he developed dyspnea, fever (38.9 °C), an increase of C-reactive protein (CRP) and w...
Kaydedildi:
| Yayımlandı: | Drug Saf Case Rep |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer International Publishing
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5005575/ https://ncbi.nlm.nih.gov/pubmed/27747720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40800-015-0010-8 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|